HAUPPAUGE, NY / ACCESSWIRE / July 21, 2022 / Emergent Health Corp. (“Emergent”) (OTC PINK:EMGE) announces it is closing in on the acquisition of Regen Biowellness, Inc. (“Regen”), a distributor of various products in the plant-based and regenerative medical fields. The acquisition was subject to Regen having resolved and finalized a settlement with respect to all its litigation. Regen is now ready to advance its business model and pursue its acquisition by Emergent. On July 19, 2022, Regen’s Bankruptcy Motion to Dismiss was approved by the US Bankruptcy Court in New Jersey. The Acquisition is expected to close on or about August 1st, 2022.
Jim Morrison, President and CEO of Regen has agreed to join Emergents Board of Directors upon the acquisition of Regen and additionally become the full-time CEO of Emergent upon the acquisition of Evolutionary Biologics. Emergent recently executed a letter of intent to acquire Evolutionary Biologics. The acquisition is expected to close within the next three weeks.
Mr. Morrison is a legend in the personal care industry, most notably as President of L’Oréal. While at L’Oréal, Morrison oversaw growth that averaged more than 20% year-over-year. He engineered the acquisitions of Redken and Matrix and led the company during a period of unprecedented growth during his tenure. He is considered one of the top brand strategists in the personal care space. Morrison has had a long history of working with celebrities in the beauty space.
Business Week Magazine previously wrote, “Over the last two decades, Mr. Morrison has had a profound impact on the American Beauty Industry. In the industry’s history no other executive has had the level of financial responsibility or breadth of organizational experience as Jim. His devotion to, and success within the American Beauty Industry is unmatched.”
Regen Biowellness products include:
Product with Issued Patents
Immuniain TM (Immune Booster) – Irreversibly-inactivated pepsinogen fragments for modulating immune function (Immune Booster- FDA Cleared) ImmunaZin contains an FDA approved New Dietary Ingredient (NDI), and the NDI # is 1140 Patent No. US 8,309,072; Patent Issued: November 13, 2012
Pending Patent Applications
Veterinary Cannabinoid and Menthol Compositions and Methods
Application No. 16/419,392; International Application PCT/US2019/048695
Cannabinoid and Menthol Compositions and Methods
US Application No. 16/419,336; International Application PCT/US2019/048691
Thin Film Toothpaste Strip, European Application
Product Name: KidzStrips ®
Thin Film Toothpaste Strip, Eurasian Application
Product Name: KidzStrips ®
Product Name: HydroSoil ®, Water retaining Hemp enhanced fertilizer, water plant once every two weeks
Adhesive Ice Pack for muscle/joint pain to cool surface and address pain.
Patent-pending, FDA pain claim in progress. IcyEase contains menthol, menthol is an approved pain relief ingredient in the FDA’s monograph for topical pain relief
Micro Voltage Trans Derm C
Patent application in progress for pain with unique and superior absorbing features due to wearer’s movement generated Micro Voltage
Silverpro – our only FDA approved medical device for the treatment of pain. Revolutionary technology combining genuine silver yarn with low-static carbon fibers, to create the world’s most advanced-compression pain relief fabric
The acquisition of Regen, along with the human and pet related products already in the Emergent family, through its subsidiaries Emergent OTC and Emergent Medical Foods for humans, as well as Pharmazu’s products for pets, plans to create a complete human and pet portfolio of products. With the previously announced acquisition of Fusion Pharmacy on June 29th 2022, Emergent intends to be a major participant in the field of OTC human and pet products.
Jim Morrison, President and CEO of Regen Biowellness stated, “This is a watershed moment for ReGen Biowellness, but more importantly a great day for Emergent Health. The combined companies will have major product offerings in the wellness category in many different channels of distribution based on the new company’s extensive portfolio”.
James W. Zimbler, CEO of Emergent stated, “Despite adverse market conditions, demand for nutraceutical products continues to grow. We’re executing our business plan by making acquisitions of companies with tremendous products which we believe will bring organic growth, profitability and significant value for our shareholders. Following our anticipated acquisitions of Regen Biowellness, Evolutionary Biologics and Fusion Specialty Pharmacies, we plan to initiate a comprehensive investor and public relations program to drive awareness for Emergent in advance of a number of meaningful initiatives.”
ABOUT EMERGENT HEALTH CORPORATION
Emergent is developing a line of products in the field of Regenerative Medicine and improved neutraceuticals and phytonutritionals available to the general public without a prescription…. Its products comprise ingestibles as well as topicals for the whole family. The company distributes its products online and through Content Based Shopping using Influencers to position products in their produced content throughout the United States and Internationally. PharmaZu, its newly acquired subsidiary, is a pure play, e-commerce products and service provider focused on The Pet Community, Pet Pharmacy and Wellness using Influencers and their content, including the pet pharmacy, vet telehealth and pet wellness businesses. Emergent does not claim any of its products are approved by the FDA to diagnose, treat, cure or prevent any disease.
Before using any products, you should always consult with your Veterinarian and Family Doctor.
SAFE HARBOR STATEMENT
This press release contains forward-looking statements that can be identified by terminology such as “believes,” “expects,” “potential,” “plans,” “suggests,” “may,” “should,” “could,” “intends,” or similar expressions. Many forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results implied by such statements. These factors include, but are not limited to, our ability to continue to enhance our products and systems to address industry changes, our ability to expand our customer base and retain existing customers, our ability to effectively compete in our market segment, the lack of public information on our company, our ability to raise sufficient capital to fund our business, operations, our ability to continue as a going concern, and a limited public market for our common stock, among other risks. Many factors are difficult to predict accurately and are generally beyond the company’s control. Forward-looking statements speak only as to the date they are made, and we do not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.
FOR MORE INFORMATION, PLEASE CONTACT: